Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts.
On September 17, 2025, Regeneron Pharmaceuticals Inc. reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of semaglutide and trevogrumab reduced fat mass by up to 27.1%, compared to 15.7% for semaglutide monotherapy, while preserving significantly more lean muscle mass. Overall weight reduction ranged between 9.9% and 13.4% across treatment groups in the 599-patient study.
Additionally, Regeneron Pharmaceuticals Inc. announced that the monitoring committee recommended early crossover in its Phase 3 Optima trial of garetosmab for fibrodysplasia ossificans progressiva, after showing a 94% reduction in new bone lesions versus placebo. The company intends to expand Phase 3 testing to pediatric patients next year and submit a U.S. regulatory application for garetosmab by the end of 2025.
Regeneron Pharmaceuticals Inc. is a global pharmaceutical company that researches, develops, manufactures, and markets treatments for a wide range of diseases, including its EYLEA injection for severe retinal disorders. It is one of the Best Widow and Orphan Stocks.
READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.
